ChromaDex Patent-Damage Claims Against Elysium Limited by Judge

Claims by ChromaDex and Dartmouth College of alleged patent infringement by Elysium Health over vitamin B3 supplements will be limited to conduct that occurred before May 13, 2017, when licensing rights were granted to another company, a federal judge ruled.

• “A plaintiff does not have the right to prevent a defendant from using a patent if another party has the right to allow the defendant to use the patent,” U.S. District Judge Colm Connolly wrote in his opinion, issued Tuesday in federal court in Wilmington, Delaware
• ChromaDex and Dartmouth filed the lawsuit in September 2018, alleging that Elysium’s Basis ...